Lancet: The effect of combination therapy in the treatment of diabetic peripheral neuropathy pain is similar to that of single therapy, and the combination therapy is well tolerated

Diabetic peripheral neuropathic pain (DPNP) is a common painful disease

OPTION-DM is a multicentre, randomized, double-blind, crossover trial in patients with DPNP with a mean daily Numerical Pain Score (NRS) of 4 or higher (on a scale of 0-10) from 13 UK centres

Between November 14, 2017, and July 29, 2019, 252 patients were screened, 140 were randomly assigned, 130 of whom started a treatment pathway (84 of whom completed at least two pathways), and The primary outcome was analysed

The result is as follows:

Table 1.

1.

2.

Table 2.

3.

Mean daily pain intensity by treatment pathway (A) and mean daily pain intensity per treatment pathway, comparing participants who started combination therapy versus continued monotherapy (B)

4.

Table 4.

This is the largest, longest, face-to-face, cross-border neuropathic pain trial ever conducted

original source

Comparison of amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM): a multicentre, double-blind, randomised crossover trial.